Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Gilenya [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;2012 May.
Food and Drug Administration (FDA) news release. FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). May 14, 2012. Available at http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm. Accessed May 28, 2012.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click